KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Net Cash Flow (2018 - 2025)

Adaptive Biotechnologies' Net Cash Flow history spans 8 years, with the latest figure at $15.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 58.49% year-over-year to $15.5 million; the TTM value through Dec 2025 reached $22.4 million, up 230.2%, while the annual FY2025 figure was $22.4 million, 230.2% up from the prior year.
  • Net Cash Flow for Q4 2025 was $15.5 million at Adaptive Biotechnologies, up from $11.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $141.1 million in Q3 2022 and bottomed at -$127.6 million in Q4 2022.
  • The 5-year median for Net Cash Flow is $3.5 million (2023), against an average of -$2.6 million.
  • The largest YoY upside for Net Cash Flow was 328.42% in 2022 against a maximum downside of 865.46% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at $16.7 million in 2021, then crashed by 865.46% to -$127.6 million in 2022, then skyrocketed by 81.47% to -$23.6 million in 2023, then soared by 141.27% to $9.8 million in 2024, then surged by 58.49% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Net Cash Flow are $15.5 million (Q4 2025), $11.8 million (Q3 2025), and -$7.5 million (Q2 2025).